Patients experienced rapid and sustained relief of symptoms and improved quality of life, as measured by SNOT-22. Improvement began as early as Week 4 and was maintained through Weeks 24 and 52 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) (key secondary endpoints).6,a
a 22-item Sino-Nasal Outcome Test (SNOT-22) score (range 0 to 110): reduced score indicates improvement.1
SNOT-22 includes 22 items assessing symptoms and symptom impact associated with CRSwNP.
SNOT-22 had a 2-week recall period. The meaningful clinically important difference is 8.9.6
Q2W, once every 2 weeks; INCS, intranasal corticosteroid.See more about how DUPIXENT can improve symptoms & quality of life